Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1998

View Archived Issues

Company Profile: Nymox

Major innovations fuel R&D at Astra

Agents for chronobiological disorders synthesized at Glaxo

PKC modulators for proliferative disorders described by Georgetown U.

New AIDS therapies in development in Korea

Indole endothelin antagonists prepared at Pfizer

Antitumor and antiviral distamycin derivatives from Pharmacia & Upjohn

Flavopiridol analogues as inhibitors of cyclin-dependent kinases

BMS discloses new Taxol derivative

Phenylglycine derivatives with mGluR-antagonist activity disclosed by Lilly

Positive U.S. phase II results for Thymoglobulin in preventing kidney transplant rejection

Anti-TNF strategy in MS treatment should be reconsidered

Rate-independent profile of antiarrhythmic agent suggests improved therapeutic potential

BioMarin's lead enzyme replacement therapy enters clinical trials

New test for cardiovascular disease risk assessment from Myriad Genetics

FDA panel recommends approval of Verdia

In vivo efficacy reported for angiotensin II blocker

EUK-134 effective in animal model of stroke

Allelix: Q1 1998 highlights

Antihypertensive efficacy described for Novartis' dual ACE/NEP inhibitor

Phase II trials of Sibia's Parkinson's disease Rx begin

Japanese approval for Biora's periodontal disease product

Pacific's cancer immunotherapy proves highly effective in rat metastatic mammary tumor model

Vaccine delivery joint venture finalized by Endorex and Elan

Viragen seeks to become fully integrated blood products company

ACT evaluated in second phase I trial in HIV/AIDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...